Tech Company Financing Transactions
EnGeneIC Funding Round
EnGeneIC closed a $10 million Series B funding round on 1/7/2015. Investors included GRT Capital Partners and Foley Ventures.
Transaction Overview
Company Name
Announced On
1/7/2015
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Series B
Investors
GRT Capital Partners (Lead Investor) (Timothy Krochuk)
Proceeds Purpose
EnGeneIC will use the proceeds from the financing to advance the clinical development of its antibody-targeted, EDV� nanocell technology platform.
Company Information
Company Status
Private & Independent
Industry
Nanotechnology
Mailing Address
275 Madison Ave. 27th Floor
New York, NY 10016
USA
New York, NY 10016
USA
Phone
Undisclosed
Website
Email Address
Overview
EnGeneIC develops and commercializes the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Himanshu Brahmbhatt
Chief Executive Officer
Jennifer MacDiarmid
Chief Financial Officer
William Harris
Chief Operating Officer
David Seaton
VP - Bus. Development
Nick Rengel
VP - Manufacturing
Blair Paton
VP - Operations
Scott Pattison
Browse more venture capital transactions:
Prev: 1/7/2015: NanoLumens venture capital transaction
Next: 1/7/2015: SonarMed venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on funding rounds that are announced publicly. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs